Possible beneficial effects of neutralizing antibodies and antibody-dependent, cell-mediated cytotoxicity in human immunodeficiency virus infection.

We studied the relationship between early human immunodeficiency virus type 1 (HIV-1) specific immune responses and pathogenesis of infection in participants enrolled in the multicenter AIDS cohort study (MACS). Sera collected at 6-month intervals for 2 years (visit 1-5) from 39 persons who seroconverted by enzyme-linked immunosorbent assay (ELISA) 6 months (visit 2) after enrollment were examined for isotype-specific Western blot reactivity, neutralizing antibodies (NA) against two divergent strains of HIV-1 (HIV-1IIIB and HIV-1RF), and for antibodies capable of participating in antibody-dependent, cell-mediated cytotoxicity (ADCC). These results were compared with changes in CD4+ cell number and episodes of lymphadenopathy. Twenty-five subjects had antibodies of at least one isotype reactive to at least one HIV-1 protein by Western blot at visit 1, before they became ELISA positive. NA reactive with HIV-1IIIB were detected before those reactive with HIV-1RF. NA were first observed in 11 sera at visit 2, in 22 sera at visit 3, and in 3 sera at visit 4; sera from three patients remained nonneutralizing through visit 5. In most cases, NA were detected after a decline in CD4+ cell numbers. The data are consistent with the interpretation that NA develop after about 16 to 18 months of declining CD4+ cell numbers, following which the rate of decline in CD4+ cell numbers slows. In contrast, HIV-1 envelope antigen-specific ADCC responses were first observed in 11 subjects at visit 1 when all 39 were NA and ELISA negative, in 12 subjects at visit 2, in 13 subjects at visit 3, and 1 subject at visit 4. Early ADCC responses were associated with high mean % CD4+ cell numbers and absence of lymphadenopathy throughout the 2-year observation period. Not all subjects who developed ADCC developed NA. In some subjects, ADCC and NA were detectable for the first time at the same visit, for others ADCC was detectable prior to NA, and for a few NA was detectable prior to ADCC. These findings suggest that ADCC and neutralization are mediated by different antibody populations, that they may partially inhibit the progress of HIV-1 infection, and that the late appearance of NA may relate to the failure of immunity to effect recovery from this infection.

[1]  M. Reitz,et al.  Envelope sequences of two new United States HIV-1 isolates. , 1988, Virology.

[2]  B. Moss,et al.  Antibody-dependent cellular cytotoxicity specific for the envelope antigens of human immunodeficiency virus. , 1988, The Journal of infectious diseases.

[3]  R. M. Hendry,et al.  Use of a sensitive neutralization assay to measure the prevalence of antibodies to the human immunodeficiency virus. , 1988, The Journal of infectious diseases.

[4]  D. Tyler,et al.  CELLULAR ANTI-GP120 CYTOLYTIC REACTIVITIES IN HIV-1 SEROPOSITIVE INDIVIDUALS , 1988, The Lancet.

[5]  B. Walker,et al.  HIV-1 reverse transcriptase is a target for cytotoxic T lymphocytes in infected individuals. , 1988, Science.

[6]  D. Shepp,et al.  Human class I MHC-restricted cytotoxic T-lymphocytes specific for human immunodeficiency virus envelope antigens. , 1988, AIDS.

[7]  R. Schooley,et al.  Antibody-dependent cell-mediated cytotoxicity against cells infected with the human immunodeficiency virus. , 1987, The Journal of infectious diseases.

[8]  E. Fenyö,et al.  Antibody-dependent cellular cytotoxicity-inducing antibodies against human immunodeficiency virus. Presence at different clinical stages. , 1987, Journal of immunology.

[9]  D. Heitjan,et al.  Antibodies to human immunodeficiency virus in human sera induce cell-mediated lysis of human immunodeficiency virus-infected cells. , 1987, Journal of immunology.

[10]  J. Phair,et al.  Infection with the human immunodeficiency virus: clinical manifestations and their relationship to immune deficiency. A report from the Multicenter AIDS Cohort Study. , 1987, Annals of internal medicine.

[11]  L. Kingsley,et al.  1986 update of HIV seroprevalence, seroconversion, AIDS incidence, and immunologic correlates of HIV infection in patients with hemophilia A and B , 1987 .

[12]  J. Phair,et al.  The Multicenter AIDS Cohort Study: rationale, organization, and selected characteristics of the participants. , 1987, American journal of epidemiology.

[13]  S. Zolla-Pazner,et al.  Nonrandom development of immunologic abnormalities after infection with human immunodeficiency virus: implications for immunologic classification of the disease. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[14]  P. Rubinstein,et al.  Prevalence, clinical significance, and strain specificity of neutralizing antibody to the human immunodeficiency virus. , 1987, The Journal of infectious diseases.

[15]  H. Jaffe,et al.  Antibody response to human immunodeficiency virus in homosexual men. Relation of antibody specificity, titer, and isotype to clinical status, severity of immunodeficiency, and disease progression. , 1987, The Journal of clinical investigation.

[16]  M. Grieco,et al.  Lymphoproliferative responses to human immunodeficiency virus antigen in asymptomatic intravenous drug abusers and in patients with lymphadenopathy or AIDS. , 1987, The Journal of infectious diseases.

[17]  B. Autran,et al.  AIDS virus-specific cytotoxic T lymphocytes in lung disorders , 1987, Nature.

[18]  B. Walker,et al.  HIV-specific cytotoxic T lymphocytes in seropositive individuals , 1987, Nature.

[19]  K. Steimer,et al.  Antibody to human immunodeficiency virus correlates with decreased T helper lymphocytes in asymptomatic individuals , 1987, Journal of medical virology.

[20]  R. Kurth,et al.  Characteristics of the specific cell-mediated immune response in human immunodeficiency virus infection , 1987, Journal of virology.

[21]  D. Cooper,et al.  Antibody response to human immunodeficiency virus after primary infection. , 1987, The Journal of infectious diseases.

[22]  P. Grob,et al.  Anti-HIV IgM antibody analysis during early manifestations of HIV infections. , 1987, AIDS.

[23]  A. Fauci,et al.  Sera from HTLV-III/LAV antibody-positive individuals mediate antibody-dependent cellular cytotoxicity against HTLV-III/LAV-infected T cells. , 1987, Journal of immunology.

[24]  J. Parker,et al.  Characterization of immunologic function in homosexual men with persistent, generalized lymphadenopathy and acquired immune deficiency Syndrome , 1987, Cancer.

[25]  J. Phair,et al.  Predictors of the acquired immunodeficiency syndrome developing in a cohort of seropositive homosexual men. , 1987, The New England journal of medicine.

[26]  H. Lyerly,et al.  Anti-GP 120 antibodies from HIV seropositive individuals mediate broadly reactive anti-HIV ADCC. , 1987, AIDS research and human retroviruses.

[27]  A. Dalgleish,et al.  Variable and conserved neutralization antigens of human immunodeficiency virus , 1986, Nature.

[28]  Hans Wolf,et al.  Identification and characterization of conserved and variable regions in the envelope gene of HTLV-III/LAV, the retrovirus of AIDS , 1986, Cell.

[29]  S. Rasheed,et al.  Virus-neutralizing activity, serologic heterogeneity, and retrovirus isolation from homosexual men in the Los Angeles area. , 1986, Virology.

[30]  J. Goedert,et al.  Long-term seropositivity for human T-lymphotropic virus type III in homosexual men without the acquired immunodeficiency syndrome: development of immunologic and clinical abnormalities. A longitudinal study. , 1986, Annals of internal medicine.

[31]  K Y Liang,et al.  Longitudinal data analysis for discrete and continuous outcomes. , 1986, Biometrics.

[32]  B. Moss,et al.  Vaccinia virus expression vector: coexpression of beta-galactosidase provides visual screening of recombinant virus plaques , 1985, Molecular and cellular biology.

[33]  R. Detels,et al.  IMMUNOLOGICAL CHANGES IN LYMPHADENOPATHY VIRUS POSITIVE AND NEGATIVE SYMPTOMLESS MALE HOMOSEXUALS: TWO YEARS OF OBSERVATION , 1985, The Lancet.

[34]  E. Gelmann,et al.  Deficient, HLA-restricted, cytomegalovirus-specific cytotoxic T cells and natural killer cells in patients with the acquired immunodeficiency syndrome. , 1985, The Journal of infectious diseases.

[35]  M. Robert-Guroff,et al.  HTLV-III-neutralizing antibodies in patients with AIDS and AIDS-related complex , 1985, Nature.

[36]  W. Darrow,et al.  Exposure to human T-lymphotropic virus type III/lymphadenopathy-associated virus and immunologic abnormalities in asymptomatic homosexual men. , 1985, Annals of internal medicine.

[37]  M. Hirsch,et al.  Antibody to lymphadenopathy-associated virus in AIDS. , 1985, The New England journal of medicine.

[38]  D. Longo,et al.  Correlation between immunologic function and clinical subpopulations of patients with the acquired immune deficiency syndrome. , 1985, The American journal of medicine.

[39]  C. Griscelli,et al.  Selective tropism of lymphadenopathy associated virus (LAV) for helper-inducer T lymphocytes. , 1984, Science.

[40]  J. Mouradian,et al.  Generalized lymphadenopathy in homosexual men. , 1983, Annals of internal medicine.